PMA device
InterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Stimulator, Electrical, Implantable, For Incontinence (EZW, Class III) · First FDA decision Aug 6, 2001, newest Nov 26, 2025Fecal incontinence and constipationOveractive bladder and urinary incontinence
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
29
PMA pathway
Device trials
28
Naming "InterStim Therapy"
MAUDE reports
0
Brand "InterStim Therapy", since 2015
PubMed studies
37
Mentioning "InterStim Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing InterStim Therapy System, Verify Evaluation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 29 decisions filed under this name.
- InterStim Therapy System, Verify Evaluation SystemPMA supplement
P970004-S439 · Decided Nov 26, 2025 · 41 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, electrical, implantable, for incontinence (EZW) · GI, Urology & Nephrology
- InterStim Therapy System, Verify Evaluation SystemPMA supplement
P970004-S409 · Decided Jan 6, 2025 · 75 days after receipt · Normal 180 Day Track
Device type: Stimulator, electrical, implantable, for incontinence (EZW) · GI, Urology & Nephrology
- InterStim Therapy System, Verify Evaluation SystemPMA supplement
P970004-S390 · Decided Dec 18, 2023 · 81 days after receipt · Normal 180 Day Track
Device type: Stimulator, electrical, implantable, for incontinence (EZW) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P970004-S353, P970004-S342, P970004-S340, P970004-S302, P970004-S292, P970004-S256, P970004-S218, P970004-S210, P970004-S172, P970004-S153, P970004-S150, P970004-S141, P970004-S124, P970004-S073, P970004-S064, P970004-S037, P970004-S023, P970004-S022, P970004-S017, P970004-S016, P970004-S014, P970004-S013, P970004-S012
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "InterStim Therapy", any status and sponsor, newest update first.
Corewell Health EastAcademic, hospital or other
NCT06150599 · 25 participants (planned) · Start Jan 27, 2026 · Primary completion Apr 1, 2028
Device: Sacral neuromodulation · For: Chronic Pelvic Pain Syndrome
Sites: Royal Oak, Michigan
- SNM vs. HBOT for Refractory IC/BPSCompleted
Shiyan City Renmin HospitalGovernment (non-federal)
NCT07091266 · 88 participants · Start Feb 1, 2021 · Primary completion Dec 31, 2022
Device: Sacral Neuromodulation (SNM) · For: Interstitial Cystitis/Bladder Pain Syndrome; Underactive Bladder
Sites: Shiyan, China
MedtronicNeuroNot on our public-company list
NCT04506866 · 148 participants · Start Aug 25, 2020 · Primary completion Dec 19, 2022
Device: InterStim Micro · For: Overactive Bladder; Fecal Incontinence; Non-obstructive Urinary Retention
Sites: Jacksonville, Florida; Tampa, Florida; Jeffersonville, Indiana · 24 sites in all
25 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "InterStim Therapy", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code EZW
68,097 reports: 34,391 malfunction, 33,649 injury, 34 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0372-2025 · Started Sep 18, 2024 · Posted by FDA Nov 13, 2024
Reason given: The Wireless Rechargers in the kits may be unable to enter a recharging session upon first use.
Cause as FDA categorized it: Under Investigation by firm · Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Z-0998-2022 · Started Feb 28, 2022 · Posted by FDA Apr 22, 2022
Reason given: There is a software anomaly with the InterStim X Clinician software application with results in the data entered in the Patient Information fields not e retained and a " Data Lost" notification being displayed.
Cause as FDA categorized it: Software Design Change · Device type: Stimulator, Electrical, Implantable, For Incontinence (EZW)
Z-1147-2015 · Started Jan 9, 2015 · Posted by FDA Jun 26, 2015
Reason given: Current labeling indicates that cycling improves device longevity in every programming scenario. However, enabling cycling at certain parameter settings may decrease the device battery longevity. With cycling enabled, longevity estimate displayed on the Model 8840Programmer may be inaccurate.
Cause as FDA categorized it: Other · Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
2 more recall records with a free account
Published research
The most relevant PubMed records for "InterStim Therapy"[tiab]. The summary above synthesizes these.
- Outcomes associated with Interstim therapy for medically refractory fecal incontinence.
McNevin MS, Moore M, Bax T · Am J Surg · 2014Evaluation Study
- Sacral nerve stimulation: Interstim therapy.
Peeren F, Hoebeke P, Everaert K · Expert Rev Med Devices · 2005Review
- Radiographic Position of the Electrode as a Predictor of the Outcome of InterStim Therapy.
Gahzi AA, Banakhar MA, Elterman DS, et al. · Int Neurourol J · 2017
- InterStim Therapy: A Contemporary Approach to Overactive Bladder.
Kohli N, Patterson D · Rev Obstet Gynecol · 2009
- Sacral Neuromodulation in Patients With a Cardiac Pacemaker.
Gahzi AA, Elterman DS, Hassouna M · Int Neurourol J · 2016
- Sacral nerve neuromodulation (InterStim). Part II: Review of programming.
Rittenmeyer H · Urol Nurs · 2008Review
- The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
Amundsen CL, Richter HE, Menefee S, et al. · Contemp Clin Trials · 2014Comparative Study, Randomized Controlled Trial
- Sacral Neuromodulation with the InterStimࡊ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Chartier-Kastler E, Le Normand L, Ruffion A, et al. · Eur Urol Focus · 2021Multicenter Study, Observational Study
- Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety.
Spinelli M, Sievert KD · Eur Urol · 2008Research Support, Non-U.S. Gov't, Review
- Modified techniques of S3 foramen localization and lead implantation in S3 neuromodulation.
Chai TC, Mamo GJ · Urology · 2001Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E, Castro-Diaz D, De Ridder D, et al. · Prog Urol · 2009English Abstract, Review
- [Sacral neuromodulation with InterStimࡊ system: Results from the French national register].
Chartier-Kastler E, Ballanger P, Belas M, et al. · Prog Urol · 2011Clinical Trial, English Abstract
Other devices of this type
Also filed under product code EZW.
- Axonics Sacral Neuromodulation SystemBoston Scientific Corporation · PMA 2026
- InterStim® Sacral Nerve Stimulation Therapy System (Urinary Control )Medtronic Neuromodulation · PMA 2018
- Neuspera Sacral Neuromodulation (SNM) SystemNeuspera Medical, Inc. · PMA 2026
- Master InterStim® Therapy System, Verify® Evaluation SystemMedtronic Neuromodulation · PMA 2022
- Interstim SystemMedtronic Neuromodulation · PMA 2011
- Medtronic Interstim Tined Lead Models 3889 & 3093Medtronic Neuromodulation · PMA 2007
- Virtis Sacral Neuromodulation SystemCirtec Medical Corporation · PMA 2023
- Verify Evaluation System for Interstim Therapy for Urinary Control and Bowel ControlMedtronic Neuromodulation · PMA 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.